Full-Time

Associate Director

Posted on 12/13/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Operations & Logistics (2)
,
Requirements
  • Proficiency in defining and implementing best-in-class R2O & Supplier Enablement procurement processes.
  • Experience in developing balanced scorecards to track procurement performance and key KPIs.
  • Deep knowledge of the requisition-to-order (R2O) process, including requisition creation, supplier selection, and order placement.
  • Strong analytical skills to analyze complex business systems and identify areas for improvement.
  • Manage relationship with key stakeholders to enable development and execution of R2O processes that effectively address business needs.
  • Doctorate degree and 3 years of procurement process management or related experience, OR Master’s degree and 10 to 14 years of procurement process management or related experience, OR Bachelor’s degree and 14 to 16 years of procurement process management or related experience, OR Diploma and 18 to 20 years of procurement process management or related experience.
Responsibilities
  • Develop and implement global standards related to Supplier On-boarding, Vendor Master Data, and Requisition to Order around which over 25K global staff will operate. Moreover, identify and recommend revisions to current procedures, programs and strategic initiatives, where necessary, consistent with best-in-practice procurement strategies
  • Develop, champion, and ensure implementation of ideas that will focus on maximizing efficiency, improving customer service and user satisfaction, standardization / globalization, robust compliance, and compliance.
  • Contribute to the design and development of global systems including the Supplier On-boarding platform and the R2O platform (Ariba)
  • Align operational plans for processes and systems to align with corporate strategy (i.e. volume growth, geographical reach, technology enablement)
  • Ownership of global Policies and Procedures specific to scope of role; ensure such policies and procedures are SOX compliant
  • Serve as the Global Subject Matter Expert (SME) on all matters relating to the scope of Supplier On-boarding, Vendor Master Data, and the Requisition to Order process and their corresponding systems. Act as an advisor to management or senior professionals, as needed
  • Independently determine the approach to project timelines and assignments and be accountable for alignment of results to objectives
  • Work closely with global team peers (i.e. US, India, etc.) to complete global project activities; this includes functions outside of P2P including Technology, GSS, Compliance, etc.
  • Accomplish results through the direct and indirect management of global teams
  • Utilize judgement to resolve system or process issues when they arise in a timely and compliant manner
  • Ensure compliance with all Amgen internal control and compliance policies.
  • Define continuous reporting capabilities on compliance and performance across R2O process.
  • Work closely with the Finance and Corporate Compliance functions to ensure compliance with controls is built into Supplier Onboarding and R2O processes and reports
  • Identify user friendly / centric solutions to drive compliance by collaborating with Procurement Digital Lead and IT function
Desired Qualifications
  • CPA or MBA preferred, but not required
  • Analytical mindset with a focus on continuous improvement and value delivery.
  • Must have experience with analytical tools (Tableau, Power BI etc.)
  • Experience with Global Procurement e-Sourcing (Ariba, Coupa, Jaggaer, iValua, etc.) and CLM Tools (e.g., Workday Strategic Sourcing, Sirion Labs), as well as Supplier Onboarding Platforms
  • 12 + years of progressive finance / accounting / business process ownership experience
  • 4+ years leadership experience directly managing and/or leading teams, projects, programs or directing the allocation of resources
  • Pharmaceutical/Biotech experience
  • Soft Skills: Strong written, verbal communication and presentation skills; Strong interpersonal skills; ability to influence personnel across functions and levels; ability to thrive in ambiguous situations and help their team operate successfully in a dynamic environment; ability to think strategically; ability to work effectively with global, virtual teams; ability to navigate ambiguity; high degree of initiative and self-motivation; ability to manage multiple priorities successfully; team-oriented, with a focus on achieving team goals; influencing and Change Management skills

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE